

# Weiru Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1842504/publications.pdf>

Version: 2024-02-01

80  
papers

8,474  
citations

101543

36  
h-index

66911

78  
g-index

84  
all docs

84  
docs citations

84  
times ranked

15164  
citing authors

#	ARTICLE	IF	CITATIONS
1	Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors. <i>Nature Biotechnology</i> , 2022, 40, 769-778.	17.5	5
2	Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1). <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 84-91.	2.8	17
3	A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRAS G12C inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2120512119.	7.1	9
4	Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3940-3955.	6.4	17
5	An Approach to Bioactivity Assessment for Critical Quality Attribute Identification Based on Antibody-Antigen Complex Structure. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 1652-1660.	3.3	1
6	Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 791-797.	2.8	3
7	Decoding non-canonical mRNA decay by the endoplasmic-reticulum stress sensor IRE1 $\hat{\pm}$ . <i>Nature Communications</i> , 2021, 12, 7310.	12.8	24
8	Identification of BRAF-Sparing Amino-Thienopyrimidines with Potent IRE1 $\hat{\pm}$ Inhibitory Activity. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2389-2396.	2.8	6
9	Activation of the IRE1 RNase through remodeling of the kinase front pocket by ATP-competitive ligands. <i>Nature Communications</i> , 2020, 11, 6387.	12.8	24
10	Activation loop dynamics are controlled by conformation-selective inhibitors of ERK2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 15463-15468.	7.1	28
11	Disruption of IRE1 $\hat{\pm}$ through its kinase domain attenuates multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16420-16429.	7.1	78
12	Single cell-produced and <i>in vitro</i> -assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar <i>in vitro</i> and <i>in vivo</i> properties. <i>MAbs</i> , 2019, 11, 422-433.	5.2	14
13	Development, Optimization, and Structural Characterization of an Efficient Peptide-Based Photoaffinity Cross-Linking Reaction for Generation of Homogeneous Conjugates from Wild-Type Antibodies. <i>Bioconjugate Chemistry</i> , 2019, 30, 148-160.	3.6	17
14	Hematopoietic Progenitor Kinase-1 Structure in a Domain-Swapped Dimer. <i>Structure</i> , 2019, 27, 125-133.e4.	3.3	26
15	A selective peptide inhibitor of Frizzled 7 receptors disrupts intestinal stem cells. <i>Nature Chemical Biology</i> , 2018, 14, 582-590.	8.0	50
16	ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 4044-4055.	7.0	36
17	Next-Generation Sequencing Reveals Novel Mutations in X-linked Intellectual Disability. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 295-303.	2.0	34
18	Unsaturated fatty acyl recognition by Frizzled receptors mediates dimerization upon Wnt ligand binding. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4147-4152.	7.1	95

#	ARTICLE	IF	CITATIONS
19	Structure of Crenezumab Complex with AÎ <sup>2</sup> Shows Loss of Î <sup>2</sup> -Hairpin. <i>Scientific Reports</i> , 2016, 6, 39374.	3.3	84
20	Discovery of (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>-)one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5650-5660.	6.4	123
21	Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5520-5541.	6.4	57
22	Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8345-8368.	6.4	24
23	Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3518-3524.	2.2	10
24	Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5121-5136.	6.4	33
25	Leveraging the Pre-DFG Residue Thr-406 To Obtain High Kinase Selectivity in an Aminopyrazole-Type PAK1 Inhibitor Series. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 711-715.	2.8	11
26	Discovery of Highly Potent, Selective, and Efficacious Small Molecule Inhibitors of ERK1/2. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1976-1991.	6.4	31
27	Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 529-541.	2.2	22
28	Regulation of the oncoprotein Smoothed by small molecules. <i>Nature Chemical Biology</i> , 2015, 11, 246-255.	8.0	107
29	Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-p<i>K</i>-<sub>a</sub> Polar Moiety. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 1241-1246.	2.8	68
30	RAF inhibitors that evade paradoxical MAPK pathway activation. <i>Nature</i> , 2015, 526, 583-586.	27.8	322
31	Fragment-based discovery of potent ERK2 pyrrolopyrazine inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4728-4732.	2.2	13
32	Inhibitors of p21-Activated Kinases (PAKs). <i>Journal of Medicinal Chemistry</i> , 2015, 58, 111-129.	6.4	98
33	Spectrum of diverse genomic alterations define non-“clear cell renal carcinoma subtypes. <i>Nature Genetics</i> , 2015, 47, 13-21.	21.4	310
34	Structural and Biochemical Analyses of the Catalysis and Potency Impact of Inhibitor Phosphorylation by Human Nicotinamide Phosphoribosyltransferase. <i>ChemBioChem</i> , 2014, 15, 1121-1130.	2.6	42
35	Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration. <i>Science Signaling</i> , 2014, 7, ra73.	3.6	52
36	Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 954-962.	2.2	19

#	ARTICLE	IF	CITATIONS
37	Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2635-2639.	2.2	29
38	Fragment-Based Identification of Amides Derived from <i>trans</i> -2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT). <i>Journal of Medicinal Chemistry</i> , 2014, 57, 770-792.	6.4	34
39	Targeting Protein-Protein Interaction by Small Molecules. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 435-456.	9.4	170
40	High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing. <i>Clinical Cancer Research</i> , 2014, 20, 2080-2091.	7.0	57
41	Back Pocket Flexibility Provides Group II p21-Activated Kinase (PAK) Selectivity for Type I 1/2 Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1033-1045.	6.4	50
42	Characterization of Oxidative Carbonylation on Recombinant Monoclonal Antibodies. <i>Analytical Chemistry</i> , 2014, 86, 4799-4806.	6.5	26
43	Reduction in lipophilicity improved the solubility, plasma protein binding, and permeability of tertiary sulfonamide RORc inverse agonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3891-3897.	2.2	45
44	Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 337-343.	2.2	15
45	Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors. <i>PLoS ONE</i> , 2014, 9, e109366.	2.5	25
46	Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5488-5497.	2.2	37
47	Structure-Based Discovery of Novel Amide-Containing Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6413-6433.	6.4	61
48	Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4875-4885.	2.2	31
49	NMR Study to Identify a Ligand-Binding Pocket in Ras. <i>The Enzymes</i> , 2013, 33 Pt A, 15-39.	1.7	7
50	Diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxycycloalkylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against $\beta$ 2-secretase-1 (BACE-1). <i>Tetrahedron Letters</i> , 2013, 54, 5802-5807.	1.4	5
51	Allosteric inhibition of BACE1 by an exosite-binding antibody. <i>Current Opinion in Structural Biology</i> , 2013, 23, 797-805.	5.7	30
52	Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3531-3538.	2.2	38
53	Structure-Based Identification of Ureas as Novel Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4921-4937.	6.4	55
54	Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12. <i>Clinical Cancer Research</i> , 2013, 19, 4433-4445.	7.0	33

#	ARTICLE	IF	CITATIONS
55	Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 5299-5304.	7.1	526
56	Recurrent R-spondin fusions in colon cancer. <i>Nature</i> , 2012, 488, 660-664.	27.8	862
57	Ras inhibition via direct Ras binding—“is there a path forward?”. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5766-5776.	2.2	87
58	A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid- $\beta^2$ Production in Vivo. <i>Science Translational Medicine</i> , 2011, 3, 84ra43.	12.4	246
59	Wnt Antagonists Bind through a Short Peptide to the First $\beta^2$ -Propeller Domain of LRP5/6. <i>Structure</i> , 2011, 19, 1433-1442.	3.3	143
60	An ARL3-UNC119-RP2 GTPase cycle targets myristoylated NPHP3 to the primary cilium. <i>Genes and Development</i> , 2011, 25, 2347-2360.	5.9	202
61	Diverse somatic mutation patterns and pathway alterations in human cancers. <i>Nature</i> , 2010, 466, 869-873.	27.8	1,189
62	Chemotaxis Receptor in Bacteria. , 2010, , 195-200.		1
63	Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 262-267.	7.1	134
64	Somatic Mutations in p85 $\beta$ Promote Tumorigenesis through Class IA PI3K Activation. <i>Cancer Cell</i> , 2009, 16, 463-474.	16.8	291
65	Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3041-3046.	7.1	1,206
66	Synthesis and Evaluation of Multisubstrate Bicyclic Pyrimidine Nucleoside Inhibitors of Human Thymidine Phosphorylase. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7807-7815.	6.4	23
67	Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 3563-3568.	7.1	76
68	Novel multisubstrate inhibitors of mammalian purine nucleoside phosphorylase. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2005, 61, 1449-1458.	2.5	7
69	The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 7505-7510.	7.1	129
70	Crystal structure of flavin binding to FAD synthetase of <i>Thermotoga maritima</i> . <i>Proteins: Structure, Function and Bioinformatics</i> , 2004, 58, 246-248.	2.6	32
71	Crystal structure of a flavin-binding protein from <i>Thermotoga maritima</i> . <i>Proteins: Structure, Function and Bioinformatics</i> , 2003, 52, 633-635.	2.6	22
72	Crystal structure of tRNA (m1G37) methyltransferase from <i>Aquifex aeolicus</i> at 2.6 Å... resolution: A novel methyltransferase fold. <i>Proteins: Structure, Function and Bioinformatics</i> , 2003, 53, 326-328.	2.6	33

#	ARTICLE	IF	CITATIONS
73	Chemotaxis Receptor in Bacteria: Transmembrane Signaling, Sensitivity, Adaptation, and Receptor Clustering. , 2003, , 197-202.		0
74	Dynamic and clustering model of bacterial chemotaxis receptors: Structural basis for signaling and high sensitivity. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11611-11615.	7.1	141
75	Structural Characterization of the Reaction Pathway in Phosphoserine Phosphatase: Crystallographic "snapshots" of Intermediate States. Journal of Molecular Biology, 2002, 319, 421-431.	4.2	170
76	In Vitro Protein Production for Structure Determination with the RTS System. , 2002, , 227-233.		0
77	Crystal Structure and Mechanism of Catalysis of a Pyrazinamidase from <i>Pyrococcus horikoshii</i> . Biochemistry, 2001, 40, 14166-14172.	2.5	96
78	Crystal Structure of Phosphoserine Phosphatase from <i>Methanococcus jannaschii</i> , a Hyperthermophile, at 1.8 Å... Resolution. Structure, 2001, 9, 65-71.	3.3	130
79	Purification, crystallization and preliminary X-ray diffraction data from selenomethionine glycylamide ribonucleotide synthetase. Acta Crystallographica Section D: Biological Crystallography, 1999, 55, 518-521.	2.5	1
80	X-ray Crystal Structure of Glycylamide Ribonucleotide Synthetase from <i>Escherichia coli</i> . Biochemistry, 1998, 37, 15647-15662.	2.5	57